Bromfenac

Nonsteroidal Anti-inflammatory Drug — SENSORY ORGANS

Key facts

Bromfenac is an ofp drug in the Nonsteroidal Anti-inflammatory Drug class catalogued in DrugCentral. It was first approved by the FDA in 2005. Its mechanism of action is classified as Cyclooxygenase Inhibitors. DrugCentral lists 3 molecular targets, including PTGS2, PTGS1 and PTGS1|PTGS2. Recorded indications include Pain, Post-Op Ocular Inflammation and Postoperative Ocular Pain.

• Approval status: ofp (first approved 2005 by the FDA).
• Drug class: Nonsteroidal Anti-inflammatory Drug.
• Mechanism of action: Cyclooxygenase Inhibitors.
• Molecular targets: PTGS2, PTGS1 and PTGS1|PTGS2 (3 listed in DrugCentral).
• Indications: Pain, Post-Op Ocular Inflammation and Postoperative Ocular Pain.
• ATC code: S01BC11 (Antiinflammatory agents, non-steroids).
• Molecular formula: C15H12BrNO3; molecular weight 334.17 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Pain
• Post-Op Ocular Inflammation
• Postoperative Ocular Pain

Contraindications (4)

• Diabetes mellitus
• Epithelial Keratopathy
• Red eye
• Rheumatoid arthritis

Mechanism & targets

• Mechanism of action (MoA): Cyclooxygenase Inhibitors
• Established pharmacologic class: Nonsteroidal Anti-inflammatory Drug

Molecular targets (3)

Target	Gene	Action	Activity
Prostaglandin G/H synthase 2	PTGS2	inhibitor	IC50 8.40
Prostaglandin G/H synthase 1	PTGS1	inhibitor	IC50 8.29
Cyclooxygenase	PTGS1|PTGS2	unknown	IC50 7.10

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2005-03-24	FDA	—	BAUSCH AND LOMB INC

ATC classification

ATC code	Therapeutic hierarchy
S01BC11	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFLAMMATORY AGENTS › Antiinflammatory agents, non-steroids

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Cataract	171.1
Toxic anterior segment syndrome	165.7
Corneal oedema	156.1
Endophthalmitis	153.4
Hypopyon	135.1
Visual acuity reduced	124.4
Ulcerative keratitis	119.8
Eye pain	110.8
Eye irritation	102.0
Product packaging quantity issue	96.4
Corneal opacity	88.2
Intraocular pressure increased	87.1

Chemical structure

• Molecular formula: C₁₅H₁₂BrNO₃
• Molecular weight: 334.17 g/mol
• CAS number: 91714-94-2
• InChIKey: ZBPLOVFIXSTCRZ-UHFFFAOYSA-N
• PubChem CID: 60726

NC1=C(C=CC=C1CC(O)=O)C(=O)C1=CC=C(Br)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Bromfenac used for?

DrugCentral lists the following indications for Bromfenac: Pain, Post-Op Ocular Inflammation and Postoperative Ocular Pain.

How does Bromfenac work?

Bromfenac is classified as Cyclooxygenase Inhibitors; its molecular targets in DrugCentral include PTGS2 (inhibitor), PTGS1 (inhibitor) and PTGS1|PTGS2.

When was Bromfenac first approved?

Bromfenac was first approved by the FDA in 2005.

What drug class does Bromfenac belong to?

Bromfenac is in the Nonsteroidal Anti-inflammatory Drug class.

What is the chemical formula of Bromfenac?

Bromfenac has the molecular formula C15H12BrNO3 and a molecular weight of 334.17 g/mol.

Sources

• DrugCentral drug card 401 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1077 — compound record and bioactivity
• PubChem CID 60726 — chemical identifiers
• DrugBank DB00963 — drug record
• FDA UNII 864P0921DW — substance identity
• DailyMed: FDA labels for Bromfenac — current prescribing information (label search)
• UniProt P35354 (PTGS2) — target protein
• UniProt P23219 (PTGS1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.